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Abstract: The landscape of rotavirus (RV) infection has changed substantially in recent years. 
Autoimmune triggering has been added to clinical spectrum of this pathology, which is now 
known to be much broader than diarrhea. The impact of RV vaccines in these other conditions 
is becoming a growing field of research. The importance of host genetic background in RV 
susceptibility has been revealed, therefore increasing our understanding of vaccine effective-
ness and giving some clues about the limited efficacy of RV vaccines in low-income settings. 
Also, interaction of RV with intestinal microbiota seems to play a key role in the process of 
infection vaccine effect. This article reviews current findings on the extraintestinal impact of 
RV infection and their widening clinical picture, and the recently described mechanisms of host 
susceptibility to infection and vaccine effectiveness. RV infection is a systemic disease with 
clinical and pathophysiological implications beyond the gut. We propose an “iceberg” model 
for this pathology with almost hidden clinical implications away from the gastrointestinal tract 
and eventually triggering the development of autoimmune diseases. Impact of current vaccines 
is being influenced by host genetics and gut microbiota interactions and these factors must be 
taken into account in the development of public health programs.
Keywords: rotavolution, extraintestinal, seizures, vaccines, autoimmunity
Introduction
For many years, rotavirus (RV) pathology has remained an undervalued condition 
and limited only to the gastrointestinal tract in the eyes of most clinicians. However, 
recent evidence from hidden systemic implications of RV infection has renewed 
interest in this pathology.1 It is now clear that RV goes beyond the gastrointestinal 
infection. The classic term “acute gastroenteritis (AGE) by RV” is increasingly 
replaced by “pathology by RV”, reflecting the well-established systemic implica-
tions of the infection.2
This “rotavolution” – or change in the traditional clinical perception of RV infection 
– has been encouraged by the impact of RV vaccines,2 through a series of published 
unexpected benefits that have scrambled the long-held perception of diarrhea as the 
main or only clinical effect of RV.3,4 In fact, diarrhea is not even necessary for the 
diagnosis of RV infection since an important percentage of rotaviremic patients show 
no clinical intestinal manifestations.
Furthermore, the recently established link between host genetics, gut microbiota 
and RV susceptibility have focused our interest on the interaction of RV with their 
host, and on the eventual “natural” resistance of some individuals to the infection or 
to the systemic spread of the virus.5
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The present review aims to expand our understanding of 
this pathology, providing an updated rationale for the concept 
“rotavolution”.2,6 We propose an “iceberg” model for the 
RV pathology (Figure 1) that explains the underestimated 
or previously ignored clinical implications of this infection 
beyond the gastrointestinal tract.
The clinical spectrum of RV
The clinical status of RV infection is updated every year, with 
growing evidence pointing to a link between RV and the develop-
ment of a number of autoimmune diseases in susceptible subjects 
as the most impactful systemic consequence. The RV pathology 
is systemic; the RV goes beyond the intestinal lumen irrespec-
tive of the presence or not of diarrhea.1 Since RV antigenemia 
detection is not a routine diagnostic tool, the impact of RV as a 
pathogen in children is underestimated, especially in the absence 
of diarrhea, where the routine RV diagnostic work-up is not even 
used. Seizures may constitute the most frequently recognized 
extraintestinal manifestation of RV infection.7
Acute extraintestinal manifestations
The role of RV infection as the cause of seizure or clinical 
neurological illness is well established in the scientific lit-
erature;8 these are the most common neurological symptoms 
with an incidence of 4.0% to 7.7% of patients, respectively.7 
Furthermore, several reports described diffuse cerebral white 
matter lesions in neonates with RV-associated seizures.9 
The pathophysiological mechanism of RV-induced seizure 
remains elusive. A hypothesis has been proposed that argues a 
key role for the viral nonstructural protein 4 (NSP4) through 
a disruption of Ca2+ homeostasis that may result in neurotox-
icity and neurotransmitter dysregulation.10 NSP4 has been 
demonstrated to act as an enterotoxin-inducing secretion of 
Cl− ions and water through phospholipase-dependent eleva-
tion of cytosolic Ca2+. However, this effect was not limited to 
the intestinal cells as NSP4 can bind to the surface of various 
cell types through interaction with glycosaminoglycans.11 
Thus, the pathophysiological effects of NSP4 may have a 
broader cellular tropism and exert a wider range of physi-
ological effects in the host. NSP4 has also been shown to 
have inherent membrane destabilizing properties.12 In this 
vein (see also below), it has been proposed that changes in 
NSP4 susceptibility may affect the impact of RV vaccines 
in seizures.13
Another possible explanation for the RV-induced seizure 
is through direct central nervous system (CNS) infection 
Figure 1 The “iceberg” model of Rv infection proposal: AGe and diarrhea are just the most obvious and frequent clinical picture of the pathology by Rv. 
Notes: Systemic viral spreading occurs and might produce several other extraintestinal manifestations such as seizures in the CNS (Table 1). Moreover, Rv infection may 
be a trigger for the development of autoimmune pathology in individuals with a specific genetic background through a proposed mechanism of immune tolerance breakdown 
at early ages.
Abbreviations: AGe, acute gastroenteritis; CNS, central nervous system; Rv, rotavirus.
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action.14 This hypothesis is supported by several studies dem-
onstrating RV detection on spinal fluid,15 and by experimental 
animal models.16 However, RV evidence has not been sought 
in spinal fluid in all cases nor the pathogenic mechanism 
established.
Other possible acute extraintestinal manifestations are 
listed in Table 1; these are mainly based on case reports and 
therefore it is more difficult to estimate their real burden.
Clinical significance of antigenemia
RV antigenemia and ribonucleic acid (RNAemia) detection 
are common findings in RV infection17,18 even in the absence 
of diarrhea;16 furthermore, these features have recently been 
linked to increased severity of fever and vomiting by an 
unknown mechanism,19 and particularly associated to the RV 
genotype G1P[8]7 infections. However, no correlation between 
RV viremia or antigenemia and diarrhea has been found.
Previously, the activation of dendritic cells in the acute 
phase of infection appeared to correlate with levels of anti-
genemia, and a high prevalence of NSP4 gene was detected 
in peripheral blood mononuclear cells, suggesting white 
blood cells as the source of extraintestinal viral replication.20 
Furthermore, a correlation between cytokine levels and RV 
antigenemia was found in patients with fever, suggesting that 
the severity of systemic infection contributes to the systemic 
manifestation of disease.21
Trigger for autoimmune diseases
The role of RV as an environmental trigger of several autoim-
mune diseases has been the focus of interest in the last few 
Table 1 extraintestinal manifestations of Rv infection.
1. Infectious/extraintestinal symptoms/diseases
Neurological symptoms  
 Benign afebrile convulsionsa
 Febrile convulsions
 Other seizures (febrile or afebrile)
 epilepsy
 Acute encephalitis
 Acute cerebellitis
 Encephalopathy (with specific white matter pattern on magnetic resonance)
 Transient acute flaccid paralysis
 Opsoclonus-myoclonus syndrome
Neonatal complications  
 Neonatal necrotizing enterocolitis
 Cystic periventricular leukomalacia
Splenic lesions (transient or recurrent)  
Acute arthritis  
Pneumonia  
Acute hemorrhagic infantile edema  
Systemic inflammatory response  
Cutaneous vasculitis  
Rhabdomyolysis  
Pancreatitis  
Hemophagocytic lymphohistiocytosis  
Reye or Reye-like syndrome  
Disseminated intravascular coagulation  
Hepatitis  
Myocarditis  
2. Autoimmune diseases
Diabetes mellitus  
Celiac disease  
Opsoclonus-myoclonus syndrome  
Myasthenia gravisb  
Uveitisb  
Notes: aMost frequent extraintestinal presentation described in the literature. bBased only on experimental/animal models. The list shows clinical entities different to 
diarrhea that have been reported or suggested to be related to Rv infection, (1) or triggered by Rv infection in susceptible subjects (2). These symptoms can be present alone 
or in combination, with or without diarrhea. See text for further explanations. Adapted from J Infect, 72 Suppl, Rivero-Calle I, Gómez-Rial J, Martinón-Torres F, Systemic 
features of rotavirus infection, S98–S105, copyright 2016, with permission from elsevier.2
Abbreviation: Rv, rotavirus.
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years.22 Special attention has been paid to celiac disease, 
an autoimmune enteropathy, where a high frequency of RV 
infections may increase the risk of celiac disease in child-
hood in genetically predisposed individuals.23 Frequent RV 
infections during infancy predicted a higher risk of celiac 
disease in childhood with a relative risk of 3.76 for individuals 
with two or more infections.23 A study carried out in Italian 
patients demonstrated that children born in the summer were 
at higher risk to develop celiac disease than subjects born in 
other seasons; this study pointed to the coincidence in the 
timing of the first introduction of gluten and the highest peak 
of RV infection as possible causes.24
In a recent study Kemppainen et al25 showed that this risk 
was modified by human leukocyte antigen (HLA) genotype, 
gluten consumption, breastfeeding and also RV vaccination, 
indicating complex interactions among infections, genetics, 
and diet in the development of celiac disease.
The mechanism for this association is unclear. Several 
authors have proposed a hypothesis of molecular mimicry 
between RV capsid protein VP7 and the human-tissue trans-
glutaminase, the main autoantigen of the celiac disease.26 It 
has been shown that VP7 can be recognized by certain anti-
transglutaminase antibodies present in the serum of celiac 
patients; moreover, these antibodies are present before the 
onset of the celiac disease, preceding the detection of anti-
transglutaminase and anti-endomysium antibodies. However, 
Ziberna et al27 have recently questioned this hypothesis in a 
study that showed lack of evidence for this RV-dependent 
molecular mimicry as a trigger for celiac disease.
Lastly, another interesting mechanism has been proposed 
by Bouziat et al28 supporting a role for infection with reovi-
rus (the double-stranded RNA virus family to which the RV 
belongs to) in triggering the development of celiac disease. 
Using a viral infection model, the authors showed that reo-
virus infection disrupts intestinal immune homeostasis at 
inductive and effector sites of oral tolerance, by suppressing 
peripheral regulatory cells conversion and promoting an 
exacerbated immune response to dietary antigens, in a type 
one interferon (IFN)-related pathway.28
Similarly, RV infection has been claimed as a triggering 
factor for type I diabetes mellitus, an autoimmune endocri-
nopathy leading to selective destruction of insulin-producing 
pancreatic beta cells.29 Data from experimental animals as 
well as in vitro studies indicate that RV, like other viruses, 
is clearly able to modulate the development of diabetes 
via different mechanisms, including direct-beta cells lysis, 
bystander activation of autoreactive T cells, suppression of 
regulatory cells, and molecular mimicry.30,31 However, the 
exact mechanism is not entirely clear and some authors 
consider this association unlikely.32
Using a bioinformatics approach, RV VP6 protein has also 
been identified as a potential threat for myasthenia gravis, a 
chronic muscular neurodegenerative autoimmune disorder.33 
In this in silico study, most conserved structural protein VP6 
matches at two regions with ryanodine receptor, the autoim-
mune target associated with the myasthenia. Furthermore, 
it was observed that these regions remain conserved in all 
circulating RV strains and showed significant antigenicity 
with respect to myasthenia-associated HLA haplotypes.
The lessons learnt from RV 
vaccination
Implementation of RV vaccines has substantially decreased 
hospitalizations from RV and all-cause AGE among children 
<5 years of age.34 Vaccination has also had an indirect effect 
among unvaccinated older children and young adults.35 More 
surprisingly, the introduction of RV vaccine has also impacted 
on extraintestinal RV manifestations in a way that we are just 
beginning to understand.
Impact of Rv vaccine on seizures
Payne et al4 were the first to demonstrate that a full course 
of RV vaccination significantly reduced the risk of child-
hood seizures during the year following vaccination, with 
an 18–21% decrease in relative risk of seizures requiring 
hospitalization as compared with children not receiving the 
vaccine. Several other teams have found similar protective 
effects for RV vaccine against seizures and convulsions,13,36 
even in a moderate vaccine coverage scenario (Figure 2). 
The unexpected benefit of RV vaccination in these studies 
seems more marked in the youngest infants (<5 years). Yeom 
et al13 described changes in the clinical characteristics of RV-
associated seizures after the introduction of RV vaccines, with 
more common afebrile seizures and a longer interval between 
gastroenteritis symptoms and the onset of seizures. Action on 
NSP4 is identified as the cause of this altered clinical course, 
related to changes in NSP4 immunity and the generation of 
anti-NSP4 IgG antibodies after vaccination.37
In contrast, a recent ecological study carried out in 
Spanish (Valencia; southeast Spain) children <5 years old 
by Orrico-Sánchez et al38 has reported a lack of impact of 
RV vaccine on seizure hospitalization rates. There are some 
issues in the study by Orrico-Sánchez et al38 that might help 
to explain the differences with all the other studies (Figure 
2). For instance, the authors included primary care patients 
and used absolute figures instead of rates. In addition, these 
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authors used a mixed Poisson regression model involving 
multiple variables (including vaccination coverage) to avoid 
confounder effects. However, this model includes variables 
such as time since vaccine introduction, which could be 
highly correlated with vaccination coverage (as time goes by, 
the vaccination coverage should increase), which can result 
in overfitting and statistical noise. Despite this the study 
states no impact of RV vaccine on seizures hospitalization, 
it is remarkable that the trend shown by their data indicates a 
relative risk in the same direction as the studies with positive 
findings.38 More recently, Biggart et al39 have also published 
a lack of effect of the monovalent RV vaccine on childhood 
seizure hospitalizations in the UK using an interrupted time 
series analysis.
If there is a beneficial impact on seizures and whether 
there is a potential benefit exerted by RV vaccines mainly 
due to the prevention of RV infections in infants otherwise 
susceptible to the neurological tropism of RV, and/or a true 
heterologous effect of the vaccine, remains unknown.2 Indeed, 
now more than ever, more studies are needed to clarify the 
effect of RV vaccines on seizures.
Impact of Rv vaccines on autoimmune 
manifestations
Vaarala et al40 reported that RV vaccination did not alter the 
risk of celiac disease and type I diabetes. In contrast, the 
recent study by Kemppainen et al25 proposed a protective 
association between RV vaccine and the development of 
celiac disease, considering RV as an important environmen-
tal factor for triggering autoimmunity. This study showed 
a reduced risk of celiac disease autoimmunity in children 
vaccinated against RV who had been introduced to gluten 
Payne et al; 0.82 (0.73, 0.91)a
Payne et al; 0.79 (0.71, 0.88)b
Pardo-Seco et al; 0.84 (0.76, 0.92)c
Pardo-Seco et al; 0.66 (0.60, 0.73)d
Pardo-Seco et al; 0.81 (0.73, 0.90)e
Pardo-Seco et al; 0.57 (0.51, 0.65)f
Sheridan et al; 0.64 (0.56, 0.74)g
Sheridan et al; 0.62 (0.48, 0.80)h
Sheridan et al; 0.60 (0.51, 0.70)i
Sheridan et al; 0.56 (0.43, 0.73)j
Pringle et al; 0.95 (0.94, 0.95)k
Orrico-Sanchez et al; 0.95 (0.88, 1.03)l
Orrico-Sanchez et al; 0.96 (0.86, 1.05)m
Orrico-Sanchez et al; 0.95 (0.84, 1.08)n
Burke et al; 0.76 (0.67, 0.87)o
Burke et al; 0.86 (0.75, 1.00)p
Unpublished data, Salas, 2019; 0.89 (0.81, 0.99)q
Unpublished data, Salas, 2019; 0.84 (0.75, 0.95)r
Unpublished data, Salas, 2019; 0.70 (0.64, 0.77)s
Unpublished data, Salas, 2019; 0.85 (0.76, 0.95)t
Unpublished data, Salas, 2019; 0.78 (0.67, 0.90)u
Unpublished data, Salas, 2019; 0.57 (0.51, 0.64)v
0.5 0.6 0.7 0.8
RR reported
0.9 1.0 1.1
Figure 2 Data from different studies indicating the relation existing between Rv vaccination coverage and seizures/convulsions expressed as RRs and their 95% CI.
Notes: RR values below one suggest a heterologous effect or an unforeseen direct effect of the Rv vaccine that would favor a lower incidence of seizures/convulsions in 
the child population. aPayne et al4 first-ever seizures; bPayne et al4 all seizures; cPardo-Seco et al3 (AKS) in year 2007; dPardo-Seco et al3 AKS in year 2010; ePardo-Seco et 
al3 convulsions in year 2007; fPardo-Seco et al3 convulsions in year 2012; gSheridan et al72 any emergency department presentation; hSheridan et al72 any hospital admission; 
iSheridan et al72 first emergency department presentation; jSheridan et al72 first hospital admission; kPringle et al73 seizure rates; lOrrico-Sánchez et al38 vaccine coverage 
1%–19%; mOrrico-Sánchez et al38 vaccine coverage 20%–39%; nOrrico-Sánchez et al38 vaccine coverage >39; oBurke et al74 full vaccination; pBurke et al74 partially vaccinated; 
Unpublished data AKS and Rv vaccination coverage 1%–14%; Unpublished data AKS and Rv vaccination coverage 15%–29%; Unpublished data AKS and Rv vaccination 
coverage >29%; Unpublished data convulsions and Rv vaccination coverage 1%–14%; Unpublished data convulsions and Rv vaccination coverage 15%–29%; Unpublished data 
convulsions and Rv vaccination coverage >29%.
Abbreviations: AKS, all kinds of seizures; RV, rotavirus.
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before 6 months of age, with a HR of 0.57. More studies are 
needed to clarify the effects of RV vaccines on autoimmune 
manifestations.
Molecular mechanisms involved in the 
systemic interaction of Rv
The underlying molecular mechanism of RV attachment and 
entry into host is now well established (Figure 3). Trypsin-
like proteases from the host intestinal lumen cleave the 
VP4 capsid protein to produce an N-terminal VP8* and the 
C-terminal VP5* peptides. This proteolytic processing of the 
outer viral spike VP4 seems essential for infectivity,41 lead-
ing to a more stable, rigid spike structure and displaying the 
distal lectin domain of VP8* molecule for receptor binding 
and attachment to the mucosal epithelia.42
The ligands for VP8* in host epithelia have been identi-
fied as oligosaccharides of the histo-blood group antigens 
(HBGAs) family, present in mucosal secretion, epithelial 
intestinal, and red blood cells.43 All of these HBGAs have 
in common an α-1,2-fucose linked residue, added by the 
α-1,2-fucosyltransferase enzyme, encoded by the FUT2 
gene. FUT2-null homozygotes determine the non-secretor 
phenotype; the evidence suggesting that homozygote carri-
ers develop a natural resistance to RV infection. Thus, FUT2 
expression seems to be relevant for viral infectivity and serves 
as a marker for host susceptibility.
However, the mechanism for viral dissemination from 
the gut is not clear. A neonatal mouse model of RV infection 
suggested that extraintestinal spread occurs via a lymphatic 
pathway, is primarily determined by non-structural protein 
NSP3, and can be modified by the VP6 capsid protein.44 Cells 
from the lymphocytic or myeloid lineage were proposed as 
viral replication sites during the extraintestinal spread.20
RV tropism toward neuronal cells could in some way 
explain why the CNS is the main focus of extraintestinal 
affectation, and the viral dissemination mechanism could 
involve the attachment to HBGAs or other specific cell 
receptors. A mechanism of retrograde axon transport has 
also been proposed, whereby synaptic vesicles returned to the 
CNS from axon terminals, as described for other pathogens 
(herpesvirus, rabies, polio virus).45
Overall, it seems that viral spread depends on viral factors 
(NSP3, VP6), but other components of the process might also 
be related to genetic host. Recently, a blood-whole transcrip-
tome analysis has revealed that the host downregulates gly-
cophorin expression in a suggested mechanism of viral spread 
inhibition.46 Glycophorins are cell-membrane glycoproteins 
rich in sialic acid, a monosaccharide often associated in the 
literature with RV interaction.47 The role of this mechanism 
in avoiding systemic spread remains to be clarified.
The role of the host in RV infection
Host genetic component in Rv infection
It has been proposed that the HBGAs of the host play an 
important role in RV cell attachment.48 These HBGAs contain 
a carbohydrate structure, namely H type I antigen, whose 
synthesis is dependent on the FUT2 gene expression, which 
determines the secretor status. There is abundant evidence 
in the literature suggesting a strong association between the 
FUT2 gene and risk of infection with RV and other entero-
pathogens such as norovirus.5,49,50 Individuals with secretor 
phenotype have an increased susceptibility to RV, especially 
to P[8] genotype; conversely, severe RV gastroenteritis is 
virtually absent among children without FUT2 expression in 
the intestinal epithelium.51 In addition, FUT3 – also related to 
HBGA expression and determinant of the Lewis antigen – has 
been proposed as a potential determinant of host susceptibility 
to RV.49 The recent meta-analysis by Bustamante et al50 points 
to the single-nucleotide polymorphism rs601338 (W154X) in 
the FUT2 gene as the causal variant in diarrhea at 1 year of 
age. The A-allele at this position results in a truncated protein 
and a lower risk of diarrhea caused by RV and norovirus.50
The host susceptibility to RV infection mediated by FUT2 
and FUT3 is RV genotype dependent.49 RV P[8] infects exclu-
Host
● Genetics (FUT2, FUT3)
● Glycomics
● Immune response (IFN pathway)
RV
● G and P genotypes
● NSP1
Microbiota
Vaccines
● Composition
● Microbiota
Figure 3 Interactions in Rv pathology: host, microbiota and Rv.
Notes: Host background includes genetics through expression of histo-blood 
groups in epithelia, glycomics with the importance of sugars for Rv interaction with 
host cells, and the IFN pathway, key in immune host defense. Intestinal microbiota 
composition and metagenome influence the course of RV infection through 
interactions between commensal microbial flora and pathogen.  RV proteins (VP4 
and vP7) determined by G and P genotypes and enterotoxin NSP1 play an important 
role in Rv attachment, cell internalization and pathogeny. Overall, effectiveness of 
RV vaccines may be influenced by all these elements.
Abbreviations: IFN, interferon; Rv, rotavirus; NSP1, nonstructural protein1. 
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sively Lewis- and RV secretor-positive children, in contrast 
to RV P[6] strains that infect mainly Lewis-negative children, 
regardless of their secretor FUT2 status.
In view of these findings, differences in host genetic 
susceptibility could have implications in vaccine efficacy 
and management. The P[8] genotype is the main component 
of the two licensed RV vaccines, therefore the proportion 
of Lewis-negative individuals must be taken into account 
in order to assess the vaccine efficacy. Thus, for instance, 
it is reasonable to speculate about a lower vaccine efficacy 
in Lewis-negative individuals;49 evidence in this direction 
has been recently provided by Bucardo et al by analyzing 
Nicaraguan children.52 In particular, the predominance of 
Lewis-negative phenotype among African populations is 
worth noting,53 as these population differences in HBGA 
expression may be responsible for discrepancies in the 
vaccine protection detected for the current RV vaccines in 
low-income vs high-income settings.54
Additionally, it was proposed that neonatal resistance 
to the P[8] and P[4] genotypes could be explained by the 
absence of Lewis antigen on the cell surface, as young chil-
dren are usually Lewis-negative until 1–2 months of age.55 
Thus, neonatal children might be susceptible to RV P[6] 
genotypes only, and not to P[8] and P[4] genotypes.
The host microbiota perspective
New evidence points to the host gut microbiota as a key player 
necessary for a viral pathogen to cause infection.56 Data from 
experimental studies demonstrated that the use of germ-free 
animals or antibiotic treatments results in a reduced rate of 
RV infection.57 These findings highlight the importance of 
the presence of certain bacterial types in the gut microbiota 
for RV attachment and infection. This microbiome composi-
tion is also related to HBGA and host genetics.5 The intes-
tinal microbiota itself affects host intestinal glycosylation 
patterns and mucin production, including fucosylation of 
HBGA.58 The relationship between gastrointestinal viruses 
and commensal bacteria remains to be elucidated, although 
there is growing evidence indicating that RV susceptibility 
and infectivity must be understood within an integrated 
framework, whereby host genetic and gut microbiota factors 
cannot be separated.
Alternatively, HBGA, host genetic and microbiota inter-
actions may be also modulating vaccine strain replication. 
The composition of the bacterial microbiota may shape the 
response to RV vaccines,59 and this may contribute to their 
low efficacy in low-income settings. In a study conducted 
in Pakistani population, Harris et al6 have recently argued 
that RV vaccine response correlates with the infant gut 
microbiota composition. The response to the monovalent RV 
vaccine (RV1) correlated with a higher relative abundance 
of Clostridium and Proteobacteria, including Serratia and 
Escherichia coli.6 Therefore, identification of key bacteria 
that correlate with RV vaccine efficacy could be important 
for designing future interventions in low-efficacy vaccine 
settings.
Conversely, RV vaccination appears to be inconsequential 
for the process of individual microbiome establishment, as 
recently demonstrated.60 Accordingly, it seems that microbial 
colonization of the intestine occurs during the first months of 
life, and oral RV vaccination does not show any major effect 
upon the infant gut microbiota.
The immunological perspective
The mechanisms responsible for immunity to RV in humans 
are not completely understood but it seems clear that immu-
nological factors are crucial in susceptibility to RV infection 
and systemic spread. RV infects primarily enterocytes, and 
the virus is detected by cytoplasmic pattern recognition 
receptors (retinoic acid-induced gene-1, also known as 
RIG-I, and IFN-induced helicase C domain-containing 
protein 1, also known as MDA5). These immune receptors 
recognize viral RNA61 and induce type I and type III IFN 
responses62 in host. At this point, a real battle for control-
ling the IFN machinery occurs between RV and the host.63 
The nonstructural RV protein (NSP1) downregulates IFN 
expression, inducing degradation of multiple members of 
the family of the IFN regulatory factors,64 which might 
underlie the poor innate immune response to RV in the 
natural infection.65 In addition, toll-like receptor 3, another 
pattern recognition receptor, has been recently associated to 
the age-dependent resistance to RV disease in experimental 
animal models, as both proteins are expressed at higher 
levels in adult animals.66
A combination of two innate cytokines, IL-18 and IL-22, 
has been proposed as a key mediator in the clearance of RV 
by the innate immune system in mice.67 However, RV infec-
tion evades the innate immune system efficiently, indicating 
that the mediators of RV clearance might be cells of the 
adaptive immune system, as CD8+ cytotoxic T cells that 
can be detected in the blood of children with RV disease.68 
However, some authors consider that circulating RV-specific 
CD8+ T cells have a poor functional profile and are B cells 
and antibodies primary determinant in clearance of primary 
infection and absolutely necessary for development of immu-
nity against reinfection.69
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Data from mouse experimental models indicate that 
immunological effectors responsible for clearance of RV 
from blood and from intestine are similar, but it is unknown 
if these effectors are induced solely in blood or intestine or at 
both sites. Furthermore, recent studies have shown that poly-
morphisms in genes encoding factors of the immune system 
can influence the host response to infection and the course of 
disease in RV and other viral infections.70 Data from animal 
models showed that IFN-λ genetic polymorphisms affected 
host control of RV infection;71 thus, genetic variation of key 
immune mediators could potentially influence the course of 
the disease and determine the degree of viral spread.
Accordingly, deeper knowledge of the immune mecha-
nisms elicited in RV infection, especially at mucosa level, 
is necessary in order to predict the potential influence of 
immune mediator genetic variations on the course and 
evolution of infection. Similarly, to understand the “protec-
tive” effect of RV vaccines, we might hypothesize that the 
factor responsible for this protective association might be 
the prevention of the exacerbated inflammatory response 
elicited by the natural infection with the subsequent break of 
immune tolerance, as opposed to a more controlled immune 
response of vaccination. Overall, more research is warranted 
to elucidate the eventual impact of RV vaccines on autoim-
mune response.
Conclusion
We are witnessing an authentic “rotavolution” in the under-
standing of RV pathology. RV infection consequences 
might be described as an “iceberg” model whereby diarrhea 
is the most visible tip (Figure 1). Autoimmune triggering 
through RV infection constitutes an interesting mechanism 
for certain diseases; if confirmed, this finding points to new 
ways of intervention in these diseases. The role of current 
RV vaccines on these widened clinical spectra remains to 
be elucidated, and it may constitute a possible heterologous 
effect, an unforeseen direct effect, or a combination of both. 
In addition, host genetic background and gut microbiota are 
being revealed as key influential factors for RV infection 
and for vaccine effectiveness. The design of new vaccines 
and public health programs would benefit from taking all 
these interactions into account. It is now known that the 
causes of infectious diseases are genetically complex and 
multifactorial, involving complex interactions between the 
host and pathogen factors. High-throughput “-omic” strate-
gies (genomics, transcriptomics, metabolomics, glycomics, 
vaccinomics, etc) are now beginning to revolutionize the way 
we understand mechanisms of viral infection. Application 
of these strategies to the rotavolution era will shed new and 
necessary light on the RV iceberg model.
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